Aditya Birla Sun Life Pharma & Healthcare Fund
An open ended equity scheme investing in Pharma and Healthcare Services Sector
April 2026
| Equity Scheme |  |
 |
 |
 |
An open ended equity scheme investing in Pharma and Healthcare Services Sector
April 2026
| Equity Scheme | |
|
|
|
| Investment Objective | |
| The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved | |
| Fund Category: Thematic (Equity) | |
 |
|
| Fund Snapshot | |
| Date of Allotment : Jul 11, 2019 | |
| Benchmark: BSE Healthcare TRI | |
| Fund Manager -Mr. Dhaval Shah Managing the Fund Since: July 11, 2019 Experience in Managing the Fund: 6.8 Years |
|
| SIP: Daily/Weekly/Monthly: Minimum ₹ 100/-and in multiples of ₹ 1/- thereafter |
|
| Application Amount for fresh subscription: ₹ 1000 (plus in multiplies of ₹ 1) |
|
| Minimum Additional Investment: ₹ 1000 (plus in multiplies of ₹ 1) |
|
| Load Structure (as % of NAV) (Incl. for SIP) | |
| Entry Load: | NIL |
| Exit Load: | For redemption/switch-out of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil |
| Count of Securities: 38 | |
| AUM as on April 30, 2026 (in ₹Crore) | |
| Month End AUM | 900.87 |
| Monthly Average AUM | 873.94 |
| Base Expense Ratio (BER) | |
| Regular | 1.96% |
| Direct | 0.86% |
| BER excludes brokerage incurred towards execution of trades, transaction cost & statutory levies as applicable to investors. | |
| NAV as on April 30, 2026 | |
| Regular Growth | 31.61 |
| Regular IDCW$ | 20.88 |
| Direct Growth | 35.07 |
| Direct IDCW$ | 22.80 |
| $Income Distribution cum capital withdrawal | |
| Valuation Parameters | |
| Average P/E | 38.45 |
| Average P/BV | 6.14 |
| Average Dividend Yield | 0.68 |
| Sectoral Contribution(in %) |
 |
| Market Capitalisation |
 |
| Volatility Measures | |
| Portfolio Turnover | 0.25 |
| Standard Deviation | 16.05% |
| Sharpe Ratio | 1.08 |
| Beta | 0.92 |
| Treynor Ratio | 0.20 |
| Information Ratio | -0.51 |
| Rating Profile of Portfolio |  |
| Sector/Issuer Name | % of Net AUM |
| Equity & Equity Related | |
| Pharmaceuticals & Biotechnology | 77.31% |
| ● Sun Pharmaceutical Industries Limited | 13.17% |
| ● Torrent Pharmaceuticals Limited | 4.76% |
| ● J.B. Chemicals & Pharmaceuticals Limited | 4.71% |
| ● Aurobindo Pharma Limited | 4.49% |
| ● Ajanta Pharmaceuticals Limited | 4.05% |
| ● Lupin Limited | 4.00% |
| ● Mankind Pharma Ltd | 3.88% |
| ● Abbott India Limited | 3.65% |
| Emcure Pharmaceuticals Ltd | 3.32% |
| Cipla Limited | 3.30% |
| IPCA Laboratories Limited | 2.86% |
| Shilpa Medicare Ltd | 2.51% |
| CORONA Remedies Ltd | 2.24% |
| SAI Life Sciences Ltd | 2.20% |
| Alkem Laboratories Limited | 2.10% |
| Procter & Gamble Health Limited | 2.04% |
| Divi''s Laboratories Limited | 1.88% |
| SANOFI CONSUMER HEALTHCARE | 1.67% |
| Dr. Reddys Laboratories Limited | 1.45% |
| ALEMBIC PHARMACEUTICALS LIMITED | 1.35% |
| Pfizer Limited | 1.34% |
| Jubilant Pharmova Ltd | 1.20% |
| ANTHEM BIOSCIENCES LIMITED | 1.20% |
| Biocon Limited | 1.08% |
| Piramal Pharma Ltd | 1.04% |
| Gland Pharma Limited | 0.97% |
| GlaxoSmithKline Pharmaceuticals Limited | 0.85% |
| Healthcare Services | 19.60% |
| ● Apollo Hospitals Enterprise Limited | 7.20% |
| ● Fortis Healthcare Limited | 3.87% |
| Jupiter Life Line Hospitals Ltd | 1.79% |
| Thyrocare Technologies Limited | 1.58% |
| METROPOLIS HEALTHCARE LIMITED | 1.42% |
| Suraksha Diagnostic Ltd | 1.06% |
| Vijaya Diagnostic Centre Limited | 0.98% |
| Dr. Lal Path Labs Limited | 0.94% |
| Max Healthcare Institute Limited | 0.77% |
| Insurance | 1.00% |
| Medi Assist Healthcare Services Ltd | 1.00% |
| Chemicals & Petrochemicals | 0.69% |
| Vinati Organics Limited | 0.69% |
| Net Cash and Cash Equivalent | 1.39% |
| Grand Total | 100.00% |
Miscellaneous includes securities with exposure of less than 0.01%
| Scheme Name | |
| Aditya Birla Sun Life Pharma & Healthcare Fund An open ended equity scheme investing in Pharma and Healthcare Services Sector |
|
| This product is suitable for investors who are seeking*: | |
|
|
Risk-o-meter  |
Benchmark Risk-o-meter BSE Healthcare TRI  |
| *Investors should consult their financial advisors if in doubt whether the product is suitable for them. | |